GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » 3-Year RORE %

Item 9 Labs (Item 9 Labs) 3-Year RORE % : 23.78% (As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Item 9 Labs's 3-Year RORE % for the quarter that ended in Jun. 2023 was 23.78%.

The industry rank for Item 9 Labs's 3-Year RORE % or its related term are showing as below:

INLB's 3-Year RORE % is ranked better than
72.5% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 2.435 vs INLB: 23.78

Item 9 Labs 3-Year RORE % Historical Data

The historical data trend for Item 9 Labs's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs 3-Year RORE % Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.31 29.64 -1.36 -4.13 18.87

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.85 18.87 18.87 21.92 23.78

Competitive Comparison of Item 9 Labs's 3-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs's 3-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's 3-Year RORE % falls into.



Item 9 Labs 3-Year RORE % Calculation

Item 9 Labs's 3-Year RORE % for the quarter that ended in Jun. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.32--0.149 )/( -0.719-0 )
=-0.171/-0.719
=23.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2023 and 3-year before.


Item 9 Labs  (OTCPK:INLB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Item 9 Labs 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Item 9 Labs (Item 9 Labs) Business Description

Traded in Other Exchanges
N/A
Address
2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Executives
Taylor Lawrence X. Iii director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey director C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden director C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven officer: Chief Operating Officer 5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson director, officer: Chief Executive Officer 1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden director 3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen officer: CFO, Secretary, Treasurer 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan 10 percent owner 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier 10 percent owner 1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla director, officer: President 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md director, officer: President 10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership director, officer: President & CEO 10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith officer: CFO, Secretary, Treasurer 8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson officer: Chief Operating Officer 8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251